Mona McCullough, MD
Urogynecology and Reconstructive Pelvic Surgery · Zephyrhills, FLNPI 1437348422
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.4%), travel and lodging and education — rather than concentrated in one kind of arrangement. Medtronic accounts for 73.0% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $2,350 and has fallen 89.1% since, to $256 in 2025. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in FL, where the typical reported total is $5,437.
Across 53 payments — averaging $65.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Stryker$287
- Caldera Medical, Inc$89
- Astellas Pharma US Inc$85
- Axonics, Inc.$67
- Sumitomo Pharma America, Inc.$54
- plus $350 from 13 others
What the payments were for
- Travel & lodging$1,55345%
- Food & beverage$1,77251%
- Education$1244%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 28 | $2,517 |
| Stryker | 2 | $287 |
| Caldera Medical, Inc | 1 | $89 |
| Astellas Pharma US Inc | 1 | $85 |
| Axonics, Inc. | 3 | $67 |
| Sumitomo Pharma America, Inc. | 2 | $54 |
| Integra Lifesciences Corporation | 1 | $45 |
| Urovant Sciences Inc | 2 | $43 |
| Pfizer | 2 | $37 |
| Coastal Medical Technologies LLC | 1 | $35 |
| Bayer | 1 | $29 |
| Dentsply IH AB | 2 | $28 |
| Actelion Pharmaceuticals US, Inc. | 1 | $24 |
| Insulet Corporation | 1 | $24 |
| Vericel Corporation | 1 | $22 |
| Boston Scientific | 1 | $17 |
| Hologic Sales And Service, LLC | 1 | $17 |
| Novo Nordisk | 1 | $16 |
| AbbVie | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,449 in reported general payments places this provider in the 30th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.
See all urogynecology and reconstructive pelvic surgery providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 276 | $214,038 |
| MyrbetriqMirabegron | 142 | $101,866 |
| Estradiol | 210 | $12,709 |
| OsphenaOspemifene | 13 | $8,046 |
| PremarinEstrogens, Conjugated | 17 | $7,437 |
| Methenamine Hippurate | 57 | $5,551 |
| Trimethoprim | 40 | $2,585 |
| Oxybutynin Chloride ErOxybutynin Chloride | 14 | $1,515 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 65 | $1,366 |
| Estradiol (Once Weekly)Estradiol | 16 | $1,347 |
| Cephalexin | 39 | $728 |
| Cefdinir | 44 | $626 |
| FyavolvNorethindrone Ac/Eth Estradiol | 14 | $621 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 50 | $590 |
| Fluconazole | 42 | $380 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $54 | $214,038276 claims |
| Astellas Pharma US IncMyrbetriq | $85 | $101,866142 claims |
| PfizerPremarin | $37 | $7,43717 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 81 urogynecology and reconstructive pelvic surgery providers in Florida.
Other urogynecology and reconstructive pelvic surgery in Zephyrhills
- Nathan KowOrlando$116K
- Amir ShariatiCoconut Creek$106K
- Charbel SalamonOrlando$100K
- Allison WymanTampa$69K
- Nicole SzellLargo$54K
- Jose Lazaro WeissOviedo$28K
- Paul PettitJacksonville$27K
- Arash RahiCoconut Creek$23K
- Moises VirellesWellington$21K
- Marja SprockRockledge$21K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.